Changes in Red Blood Cell Transfusion Burden with Luspatercept Versus Epoetin Alfa in Patients with Lower-Risk Myelodysplastic Syndromes in the Phase 3, Open-Label, Randomized, Controlled COMMANDS Trial
Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Uwe Platzbecker(National Center for Tumor Diseases), Mrudula B. Glassberg(Bristol-Myers Squibb (United States)), David Valcárcel(Vall d'Hebron Hospital Universitari), Matteo Della Porta(University of Milan), Jake Shortt(The University of Melbourne), Amer M. Zeidan(Yale Cancer Center), Yinzhi Lai(Bristol-Myers Squibb (United States)), Ahmed Hnoosh(Bristol-Myers Squibb (United Kingdom)), Dimana Miteva(Bristol-Myers Squibb (Switzerland)), Valeria Santini(Azienda Ospedaliero-Universitaria Careggi), Shelonitda Rose(Universidad San Carlos), Rami S. Komrokji(Moffitt Cancer Center), Aylin Yücel(Bristol-Myers Squibb (United States)), Pierre Fenaux(Saint Louis University Hospital)
Cited by 1
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k